EOS imaging Receives FDA Clearance for New Software Dedicated to Sagittal Balance and Posture Analysis

FDA-Cleared software uses 3D modeling to enhance diagnosis and surgical planning of spine pathologies

Paris, September 17, 2014 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, announced today that its next-generation sterEOS 3D imaging software, sterEOS 1.6, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

The sterEOS® software provides 3D modeling of the spine and lower limbs based on scans taken with the EOS® System, and automatically calculates more than 100 clinical parameters relevant to diagnosis and surgical planning. The new sterEOS® 1.6 integrates a postural assessment feature dedicated to spine pathologies and associated surgeries that allows a fast analysis of a patient's skeletal balance and helps the surgeon plan adequate spinal surgery to maintain or restore this balance, which is often modified or lost with ageing or scoliotic deformity. The new software will be made available to existing EOS customers as a software upgrade and will be included in all new EOS system sales.

Concurrent with the FDA clearance, the benefits of EOS® and its software sterEOS® were highlighted at the 49th Annual Meeting of the Scoliosis Research Society (SRS) in Anchorage, Alaska (USA) and during an associated EOS® educational symposium that gathered more than 50 surgeons from all around the world.

The symposium, titled "Innovations in sagittal balance for scoliosis treatment" featured presentations from four leading orthopedic surgeons from the United States and France. Additionally, medical communications by EOS users during the SRS congress also highlighted the importance of sagittal balance as well as the value of 3D visualization in prognostic and surgical planning.

The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D with 50% to 85% less dose than Digital Radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction.

Marie Meynadier, CEO of EOS imaging, said, " *This new generation software release in the U.S. demonstrates our commitment to answer with EOS the medical needs of orthopaedic surgeons, amongst whom EOS users have widely contributed to a general recognition of the importance of global patient assessment and sagittal balance analysis in spine care. By continuously enhancing the capabilities of the EOS platform in support of our customers, we keep encouraging adoption by medical facilities throughout the U.S."*

For further information about the EOS® imaging or the Company's full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 33 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of more than 90 sites and by more than 500,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 3rd quarter of 2014, on October 22, 2014 (after market).

Contacts:

Anne Renevot
CFO
Ph: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)
Press relations / Calvin Allen
Ph: 646-536-7002
callen@theruthgroup.com

ELIGIBLE PEA PME